Compare
Corvus Pharmaceuticals, Inc. vs Werewolf Therapeutics, Inc. vs Incannex Healthcare Inc. vs Context Therapeutics Inc.
| Latest fiscal year | Corvus Pharmaceuticals, Inc. CRVS | Werewolf Therapeutics, Inc. HOWL | Incannex Healthcare Inc. IXHL | Context Therapeutics Inc. CNTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | n/a |
| Revenue growth (YoY) | n/a | n/a | -100.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$15.28M | -$60.82M | -$19.30M | -$36.12M |
| EPS (Diluted) | -$0.53 | -$1.33 | -$1.66 | -$0.38 |
| Operating cash flow | -$32.80M | -$60.29M | -$12.87M | -$26.39M |
| Free cash flow | -$32.97M | -$60.29M | -$12.88M | -$26.42M |
| Cash & equivalents | $4.58M | $57.05M | $67.71M | $66.00M |
| Total assets | $71.12M | $69.40M | $72.98M | $68.49M |
| Total liabilities | $9.91M | $44.59M | $5.61M | $8.02M |
| Shareholders' equity | $61.20M | $24.80M | $67.37M | $60.47M |
| Return on year-end equity | -25.0% | -245.2% | -28.6% | -59.7% |
| Shares outstanding | 74.70M | 48.60M | 12.54M | 91.88M |
Revenue, most recent five fiscal years
| Fiscal year | Corvus Pharmaceuticals, Inc. | Werewolf Therapeutics, Inc. | Incannex Healthcare Inc. | Context Therapeutics Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $0 Ended 2026-06-30 | n/a |
| 1 year earlier | n/a | n/a | $86.0K Ended 2025-06-30 | n/a |
| 2 years earlier | n/a | n/a | $12.0K Ended 2024-06-30 | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |